Thank you for Subscribing to Life Science Review Weekly Brief
Leveraging AI and DCTs has become the core imperative to developing safe therapies as fast as possible.
FREMONT, CA: For years, enhancing clinical trial outcomes has focused on lowering time and cost. That focus, and the challenges of a pandemic, has triggered the digitization of the clinical trial life cycle. Decentralized Clinical Trials (DCTs), which put the patient at the heart of the trial experience and combine digital technologies, and artificial intelligence (AI), are joining forces to transform clinical research. Organizations are coupling DCT methodologies with AI in innovative means to reshape workflows across the clinical lifecycle, from trial design and patient recruitment to evidence generation. They are seeing dramatic decreases in time and cost of clinical studies. Read on to know more.
With the analytical tools and AI, the industry can benefit from this rich data to optimize patient recruitment, boost patient retention, reduce timelines, and maximize study results in future trials. AI can expedite target validation, trial design, and patient identification. DCTs can reduce the time and cost of clinical studies by widening patient access and retention due to enabling patients to participate safely and conveniently in their homes.
DCTs also mitigate geographic, transportation, costs, and other hurdles that can enhance participants' diversity. The net impact is an enhancement in data quality as site-based transcription is avoided, plus an increase in efficiency for patients, sites, and study teams. Together, AI and DCTs can be a powerful tool.
To deploy AI with purpose, AI engines need more than just mountains of data. To offer accuracy, the data requires to be closely representative of the target population. As has been highly publicized in recent months, conventional clinical trials are often comprised of participants from urban areas and are predominantly white. DCTs drive AI engines since they inherently gather massive real-world, real-time data from diverse patient populations more inclusive of the world. By coupling both innovations, firms will enhance three crucial clinical trials, including trial design, patient recruitment, and evidence generation. AI’s continued maturation will widen its use across all stages of the patient journey and will lead to incredible breakthroughs in personalized medicine to rare diseases.